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Abstract The structural effects of the fusion peptide of feline
leukemia virus (FeLV) on the lipid polymorphism of N-
methylated dioleoylphosphatidylethanolamine were studied using
a temperature ramp with sequential X-ray diffraction. This
peptide, the hydrophobic amino-terminus of p15E, has been
proven to be fusogenic and to promote the formation of highly
curved, intermediate structures on the lamellar liquid-crystal to
inverse hexagonal phase transition pathway. The FeLV peptide
produces marked effects on the thermotropic mesomorphic
behaviour of MeDOPE, a phospholipid with an intermediate
spontaneous radius of curvature. The peptide is shown to reduce
the lamellar repeat distance of the membrane prior to the onset of
an inverted cubic phase. This suggests that membrane thinning
may play a role in peptide-induced membrane fusion and
strengthens the link between the fusion pathway and inverted
cubic phase formation. The results of this study are interpreted in
relation to models of the membrane fusion mechanism.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Biomembrane fusion is a ubiquitous process that plays a
crucial role in such fundamental events as spermatozoid-egg
fusion and mitosis. Despite this fact, the molecular rearrange-
ments of the lipids and the precise kinetic events involved are
still unclear. This is largely because the fusion event is tran-
sient and involves only local, isolated patches of lipid. Bio-
membrane fusion is a protein-regulated event [1,2]. Enveloped
virus particles use membrane fusion in order to introduce
their infective nuclear material into a host cell. The most
widely studied membrane ‘fusion protein’ is the hemagglutinin
of the in£uenza A virus [2]. This virus, like all animal envel-
oped viruses, utilises a specialised, extra-membranous glyco-
protein ‘spike’ as a fusion catalyst.
Although the initial triggers of the fusion event show great
diversity, the actual macromolecular rearrangements of the
membrane are thought to be similar for many fusing systems
[3]. The multi-step fusion process involves the merging of two
distinct, planar bilayers to form highly curved fusion inter-
mediates [4] and there has been much evidence to support
this hypothesis [5^10]. The formation of highly curved lipid
mesomorphs also occurs during the lamellar liquid-crystal/in-
verted cubic (LK/QII) phase transition and the lamellar liquid-
crystal/inverse hexagonal (LK/HII) phase transition [11]. The
ability of a number of agents to promote fusion appears to be
correlated to their ability to lower the LK/HII transition tem-
perature (TH) [12^14]. Similarly, some fusion inhibitors raise
TH [15]. Although the QII and the HII phases, which are
kinetically stable, are unlikely to exist at the site of a devel-
oping fusion pore, knowledge about the topology of the inter-
face as these phases begin to form may have implications in
biological fusion pathways.
The exact structures of the intermediates involved in the LK/
QII and LK/HII phase transitions have not been described
uniquely [16^19]. Experimental data [20] and theoretical free
energy calculations of intermediate lipid structures [21] sug-
gest that the most likely pathway is via the formation of a low
energy stalk-like structure [22], then ‘hemifusion’ intermedi-
ates (also known as transmonolayer contacts, TMCs). A re-
cent study showed that intermembrane connections could ap-
pear some 22‡C below the TH [23]. The intermembrane
connections evolve to form isolated TMCs, then aggregated
TMCs, which are a basis for HII phase growth via the for-
mation of quasi-hexagonal phase domains [23]. The integrity
of the TMC structure is the committing step in membrane
fusion. Ruptured TMCs form interlamellar attachments
(ILAs) or fusion pores. Many ILAs in close proximity may
nucleate to form QII phases. There is evidence to suggest that
specialised fusion proteins also catalyse the formation of sim-
ilar lipid intermediates [3,24^26]. Therefore, studying the
structural e¡ects of fusion peptides in the proximity of in-
verted phase boundaries provides instructive insight into the
fusion mechanism.
In this paper, we report the e¡ect of the fusion peptide from
feline leukemia virus (FeLV) on the thermotropic lipid phase
behaviour of multi-lamellar vesicles (MLVs) composed of N-
methylated dioleoylphosphatidylethanolamine (MeDOPE).
The fusion peptide of FeLV is the hydrophobic N-terminus
of p15E, itself part of the viral envelope glycoprotein spike
gp85. Sequential small angle X-ray scattering (SAXS) images
were recorded from pure lipid dispersions and lipid disper-
sions containing di¡erent amounts of FeLV peptide as the
temperature was progressively increased. We interpret the
¢ndings in relation to biomembrane fusion.
2. Materials and methods
FeLV fusion peptide was synthesised by Albachem (Edinburgh,
UK) to the sequence EPISLTVALMLGGLTVGGIAAGVGTGTK,
as used in our previous studies (e.g. [27]). MeDOPE was purchased
from Avanti Polar Lipids (Alabaster, AL, USA) and used without
further puri¢cation. A stock solution of FeLV peptide (1.0 mg/ml)
in chloroform:methanol (2:1) was prepared by thorough vortexing
and ultrasonication. An ice/water mixture ensured that sonication
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did not heat the solution above room temperature. The appropriate
amount of stock solution was dispensed to a pre-weighed amount of
MeDOPE in a Pyrex test-tube. The dissolved lipid and peptide were
then dried under a stream of oxygen-free nitrogen. The resultant lipid
¢lms were placed under vacuum overnight in the presence of phos-
phorous pentoxide (P2O5) to remove trace amounts of solvent. Each
¢lm was reconstituted in bu¡er (20 mM PIPES, 1 mM EDTA, 150
mM sodium chloride and 0.002% sodium azide at pH 7.4) and vor-
texed thoroughly for 10 min at room temperature. All samples had a
low lipid concentration of 100 mM, equivalent to 7.57% (w/v), thereby
ensuring an excess water condition. The lipid dispersions were then
subjected to ¢ve freeze-thaw cycles as previously described [27] to
ensure that the lipid was in the fully hydrated LK phase regardless
of the thermal history of the lipid.
X-ray di¡raction measurements were performed at station 2.1 of
the Synchrotron Radiation Source at Daresbury Laboratory, UK.
The X-ray wavelength was 1.54 Aî , the specimen to detector distance
was 1.5 m. A te£on-lined brass chamber with mica windows and
thermocouple was used as a sample holder and a circulating water
bath controlled the sample temperature. The temperature increased
linearly at a rate of 30 K/h, while data were collected continuously,
at a rate of two frames per minute. Geometric and detector response
corrections were applied using the XOTOKO program. Angular cal-
ibration was achieved using rat-tail collagen as a standard [28] imme-
diately prior to the exposure of each new liposomal sample. The exact
location and intensity of Bragg re£ection were determined by Gaus-
sian ¢tting, using PeakFit v4 software (Jandel Scienti¢c, Chicago, IL,
USA).
3. Results
3.1. MeDOPE control
This type of experiment may be run as a series of temper-
ature jumps, each one followed by a pause whilst the sample
equilibrates to the new temperature before a single frame of
data is obtained. Whilst this approach ensures equilibrium
across the sample, information is lost during heating. There-
fore, the approach chosen for these measurements was a con-
tinuous temperature scan, with consecutive frames of x-ray
data recording the whole transition process. In this way, it
is unlikely that the sample ever reaches equilibrium, but the
chance of observing intermediate structures is maximised.
This is only possible with bright synchrotron X-ray sources.
MeDOPE was chosen for this study because its TH of approx-
imately 60‡C is experimentally convenient, allowing for a long
temperature ramp from ambient conditions. MeDOPE is
classed as a ‘non-bilayer lipid’ [29]. Such lipids are thought
to play a role in biological membrane fusion. In addition,
MeDOPE has an intermediate spontaneous radius of curva-
ture (Ro) value [8] and has been shown to form QII phases
when treated to speci¢c thermal protocols [8,30,31]. MeDOPE
has an intermediate Ro value, so this lipid has a tendency to
form structures of intermediate curvature [8].
In the X-ray data, two sharp orders of di¡raction were
observed at 31‡C, which indexed onto a lamellar lattice (re-
ciprocal lattice ratio 0:1:2) when measured from the position
of the zeroth order. The narrow peak widths and low inco-
herent scattering inferred that most of the sample mass was in
a well-ordered lattice. The lamellar repeat distance (dL) of
MeDOPE at 31‡C was 62 Aî , which is in agreement with
Gruner et al. [8]. Fig. 1 shows the lattice basis vector lengths
of the LK and HII phase as a function of temperature. dL
increases steadily with temperature up to 54‡C. HII phase
onset is observed at approximately 60‡C in agreement with
the literature. Although both QII and HII phases of MeDOPE
can co-exist near TH [31], no QII phase re£ections were ob-
served at our relatively rapid temperature scan rate, as pre-
dicted. The exact TH is di⁄cult to ascertain because the d/1
and d/2 re£ections of both HII and LK overlie each other with
MeDOPE, making di¡erentiation between the two phases dif-
¢cult. The ¢rst re£ection unique to HII phase (d/k3) was ob-
served at approximately 60‡C. The co-existence of LK and HII
phases near the TH has been reported previously [32]. Above
62‡C, some ¢ve HII re£ections were observed, with the recip-
rocal ratio of 0:1:k3:k4:k7:k9.
The HII lattice basis vector length of MeDOPE at 60‡C was
65 Aî . Multiplying this value by the factor 2/k3 yields dH, the
distance from the centre of one HII cylinder to the next. The
calculated dH was 75 Aî , which is comparable with Gruner’s
value. dH steadily decreased to 73 Aî at 71‡C. This occurs
because the hydrocarbon chain splay is wider at higher tem-
peratures.
Fig. 2 shows the full-width at 1/e (e = 2.718) height (FW1/
eH) values for the ¢rst and second order re£ections. This
parameter is related to the sample order. The width of the
Fig. 1. Lattice basis vector length versus temperature for the LK
and HII phases of MeDOPE, as determined by TRXRD performed
at station 2.1 of the Synchrotron Radiation Source at Daresbury
Laboratory, UK. Key: E d/1, 3 d/k2, O d/k3, 7 d/2, P d/k7, a d/
k9; LK phase in hollow symbols, HII phase in black. In the shaded
area, the two phases co-exist; the re£ections in this region contain
contributions from both LK and HII phases.
Fig. 2. Variation in sample order as a function of temperature from
TRXRD results. Sample order is expressed as the full-width at 1/e
height (e = 2.73) of a Gaussian distribution ¢tted to each Bragg
peak. Symbols as in Fig. 1.
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Bragg re£ections signi¢cantly decreases from those around
50‡C, indicating that the lipid system becomes progressively
more ordered as the phase boundary approaches. This is be-
cause, close to TH, the recorded re£ection is the superposition
of a wide LK Gaussian and a narrow HII Gaussian. As the
contribution of the wide LK Gaussian decreases and the con-
tribution of the narrow HII Gaussian increases, the observed
peak appears narrow. Lipid phases may co-exist even without
thermal gradients across the sample. The observation that the
pure lipid specimen can undergo a LK/HII phase transition at
fast scan rates without entering the QII phase is in agreement
with Hui et al. [7].
3.2. MeDOPE and FeLV fusion peptide (1.0 and 0.5 mol%)
dL for both of these samples was similar to that of the pure
lipid. The FW1/eH values were slightly less than the lipid
control, indicating more order in the LK phase lattice. In the
1.0 mol% peptide sample, a shoulder was evident on both the
di¡raction orders of the LK phase at 35‡C (Fig. 3). As the
temperature steadily increased, the shoulders on both orders
of di¡raction grew and resolved into new peaks as the original
peak area diminished. These new peaks indexed to a lamellar
phase (dL = 58 Aî ). They overlapped the onset of very low
angle Bragg re£ections whose spatial frequency indexed onto
a ratio of 0:1:k2:k3. Although the spatial frequencies of only
four orders of di¡raction were observed (including the zeroth
order), both LK and HII phases can be excluded. The peak co-
ordinates indicate the emergence of a QII with a large lattice
basis vector length of 254 Aî at 44‡C (Fig. 4). These initial
dimensions are approximately 55% greater than previously
recorded QII phases [8,30,32,33]. The lattice basis vector
length decreased reciprocally with temperature to 129 Aî at
72‡C, indicating tighter curvature at higher temperatures.
The dimensions at 72‡C closely resemble those in previous
studies that classed the lipid as possessing Pn3m or Pn3 space
group symmetry (unit cell parameter = 125^140 Aî ) [8]. The
size of the QII peaks increased with temperature. The HII
phase was ¢rst observed at 71‡C, at least some 10‡C higher
than either the pure lipid sample or the 2.0 mol% peptide
sample, both of which showed close agreement with the QII/
HII transition temperature, TQH, measured by Siegel and
Banschbach, [31].
As the novel lamellar peaks disappeared at 55‡C, there was
an increase in sample disorder. The areas under the QII peaks
were much less than the areas under either the LK phase or
HII phase peaks, but the incoherent background did not no-
ticeably increase.
The 0.5 mol% FeLV peptide sample behaved similarly to
the 1.0 mol% sample. In the 0.5 mol% peptide sample, the QII
phase emerged at 53‡C, nearly 10‡C higher than the 1.0 mol%
peptide sample. The lattice basis vector length of this cubic
phase was 284 Aî at 53‡C, decreasing to 125 Aî at 72‡C. Again,
shoulders were observed on the ¢rst and second di¡raction
orders of the LK phase but these were less pronounced than
those of the 1.0 mol% peptide sample. As before, the should-
ers appeared prior to the appearance of the cubic phase and
had the same dL of 58 Aî .
3.3. MeDOPE and FeLV fusion peptide (2.0 mol%)
The highest peptide concentration gave di¡raction patterns
that were the most similar to those from MLVs composed of
pure MeDOPE. Well-ordered di¡raction was observed
throughout the temperature scan. The dL, peak areas (includ-
ing the reduction in amplitude at 60‡C), TH and the FW1/eH
were all very similar to the lipid control. Only a small amount
of QII phase was observed and then only after the HII phase
Fig. 3. X-ray di¡raction pro¢les of MLVs composed of MeDOPE
plus FeLV fusion peptide (1.0 mol%) at speci¢c temperatures. The
diagram clearly shows the emergence of a shoulder on the LK Bragg
re£ections and the onset of a QII phase.
Fig. 4. Lattice basis vector length versus temperature for the LK
and QII phases of MeDOPE plus FeLV fusion peptide (1.0 mol%)
as determined by time-resolved small angle X-ray di¡raction. The
novel lamellar phase with reduced dL can be readily observed
(crossed symbols). Onset of the HII phase occurs at the end of the
temperature scan. The shaded areas represent transition temperature
ranges, during which more than one phase is observed simultane-
ously. Symbols as in Fig. 1; QII phase symbols in grey.
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was established. This may have been accounted for by the
existence of discrete membrane patches containing low
concentrations of peptide. The peptide in these domains
may be able to interact more intimately with the phospholipid
in a similar manner to that seen for samples containing the
lower peptide concentrations. The QII phase was observed
from 66 to 70‡C and had a basis length of 148 Aî that did
not change signi¢cantly during the limited temperature range
at which it existed. At this temperature, the QII basis length
was 159 Aî for the 1.0 mol% sample and 165 Aî for the
0.5 mol% sample.
4. Discussion
These results clearly show that FeLV fusion peptide has a
marked e¡ect on the thermotropic behaviour of MLVs com-
prised of MeDOPE. This e¡ect was most evident at the two
lower peptide concentrations, when the peptide induced both
a QII structure and a novel lamellar structure.
A previous di¡erential scanning calorimetry (DSC) study
has shown that, at high concentrations, the FeLV peptide
had less e¡ect upon the TH of DPoPE than was seen at low
peptide concentrations [27]. In the same paper, using SAXS,
the presence of peptide-induced novel peaks in the HII phase
of DPoPE was also less pronounced at high peptide concen-
trations. Similarly, our X-ray data have shown that the sam-
ple containing 2.0 mol% peptide behaved like the pure lipid
control. It is possible that, at this high concentration, peptide
is simply lying along the membrane surface in su⁄ciently
large numbers to prevent the bilayer from curling into an
inverse geometry. Alternatively, peptide aggregation in these
higher concentration samples may prevent the peptide from
interacting with the phospholipid molecules in the same way.
We have already reported [34] that FeLV fusion peptide is
able to form amyloid-like cross-L ¢brils.
At concentrations of 0.5 and 1.0 mol%, the FeLV peptide
reduces the TH of MeDOPE and increases the amount of
isotropic 31P nuclear magnetic resonance [27]. The idea that
fusion peptides can induce this isotropic resonance is not new
[9,10,33]. However, our data show that the previously re-
ported isotropic resonance [27] is directly related to QII struc-
ture formation. The connection between membrane fusion
and the formation of non-bilayer phases is only valid for
systems that show these structures during the ¢rst heating
scan, as was observed here. This is the ¢rst observation, to
our knowledge, of QII phase formation by a viral fusion pep-
tide. Previously, this peptide-induced phase has only ever been
seen with MeDOPE systems containing in£uenza A fusion
peptide at temperatures above TH or in samples cooled
from TH [33]. Development of the QII phase normally takes
hours and thus cannot be correlated to the rapid fusion proc-
ess, but we have shown that FeLV peptide can reduce the time
of this transition to minutes. This suggests that the FeLV
peptide is an extremely potent trigger of highly curved inter-
mediates.
Previous DSC measurements of MeDOPE-containing
MLVs have revealed small shoulders on the low temperature
side of the TH enthalpic peak [13,34], presumably caused by
intermediates in the LK/HII pathway. Later studies using DSC
and X-ray di¡raction revealed that the LK/QII phase transition
temperature (TQ) was approximately 62‡C and that the QII
structure undergoes a phase transition to the HII phase at
higher temperatures (72^77‡C) [31]. Thus, from Fig. 3, it
can be readily observed that the FeLV peptide dramatically
reduces TQ by 18‡C, when compared to these values. The HII
phase that eventually formed had the same lattice parameters
as the pure lipid. Importantly, this indicates that the peptide
does not a¡ect Ro of this lipid species although it does have a
destabilising e¡ect upon the LK phase. A previous X-ray dif-
fraction study on MeDOPE with the fusion peptide of simian
immunode¢ciency virus revealed that the HII lattice parame-
ters were slightly less than that of the pure lipid control [32]. It
was reasoned that this fusion peptide destabilises bilayers by
increasing the strength of Ro. Importantly, the FeLV peptide
promotes the facile development of QII structures rather than
HII structures. Precursors involved in the LK/QII transition
pathway are also thought to be involved in fusion pore for-
mation [35].
An important feature of the SAXS data is the appearance
of a lamellar structure with reduced dL some 25‡C below the
TH. This structure occurs at the LK/QII transition, co-existing
with ¢rst the LK and then the QII phases. This peptide-induced
structure seems to represent a transitory stage in the LK/QII
phase transition mechanism and possibly in the multi-step
fusion event itself. The correlation of the appearance of this
novel structure with the greatly reduced TQ suggests that the
two are causally connected. We believe that this e¡ect is a
result of the peptide’s local action on the membrane rather
than due to bulk phase separation into areas of peptide-rich
and peptide-poor concentrations. This argument is supported
by the fact that no novel peaks were evident at the 2.0 mol%
peptide concentration, the concentration where phase separa-
tion would be most obvious. The available data do not deter-
mine whether the novel structure is thermodynamically meta-
stable.
There are two possible explanations for these lamellar struc-
tures of reduced dL. The thickness of the water layer between
adjacent bilayers may decrease or the lipid bilayer may thin.
Interfacial dehydration of the lipid bilayer would decrease
the dL [36]. The close approach of two membranes is hin-
dered, from approximately 20 Aî inwards, by an exponentially
increasing repulsive force [37,38]. It is necessary to displace
tightly bound water molecules from each membrane interface
[39]. Surface dehydration, by a fusion peptide, could circum-
vent repulsive forces and permit close membrane approach.
Our SAXS images reveal that the d-repeat of the bilayer de-
creased by some 8 Aî in the presence of peptide. This value is
similar to that reported by Hui et al. [36] who studied mem-
brane fusion induced by freezing and thawing. They make the
point that dehydration does not cause membrane fusion alone
but that it increases the opportunity for the event to proceed.
The ability of fusion peptides to dehydrate membrane surfaces
has already been implicated in modelling studies of a lipid-
lined fusion pore [40].
An alternative, or complementary, explanation for the ob-
served reduction in dL is bilayer compression. X-ray di¡rac-
tion studies have shown that low concentrations of alamethi-
cin adsorbed onto phospholipid bilayer surfaces can cause
bilayer thinning [41]. Wu et al. proposed that alamethicin
increases the cross-sectional area of the membrane surface
by causing lateral expansion of the lipid headgroups. The
cross-sectional areas of the lipid headgroups and hydrocarbon
chains must be matched in planar bilayers, so the hydrocar-
bon chains must increase their cross-sectional area to compen-
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sate for the peptide at the surface. As the volume occupied by
the chains is constant, there is a resultant decrease in the
bilayer thickness. Since monolayers of phosphatidylethanol-
amine lipids have a natural tendency to curl, at elevated tem-
peratures, the lipid molecules are not able to maintain cross-
sectional matching and undergo an inverted phase transition.
Like the HII phase, the QII lattice parameters decrease recip-
rocally with temperature due to hydrocarbon chain splay. At
TQH, the frustration between the free energy of monolayer
curvature strain and hydrocarbon chain stretching must be
so great that the HII phase forms.
Why does the membrane-thin structure metamorphose to a
QII phase and not HII ? At a given temperature, the monolayer
curvature free energy and the free energy involved in hydro-
carbon chain stretching governs the type of lipid phase present
[29]. No lipid assembly can fully satisfy the con£icting de-
mands of a simultaneous low curvature free energy and chain
packing free energy, giving rise to frustration. Cubic phases
have a lower free energy of curvature than the LK phase but
higher than the HII phase. Conversely, the free energy of the
chains is higher than in the LK phase but lower than the HII
phase. This means that the amount of frustration in the cubic
phase is smaller than in either the LK or the HII phases [42], so
that the cubic phase represents a compromise between the
two. Our data show that the peptide destabilises the LK phase
but stabilises lipid transition intermediates. Compared with
the LK phase, the lipid intermediates have a reduced amount
of frustration. The data show that, in the presence of fusion
peptide, the inverted structure formed is a QII structure. The
initially large lattice parameter of this phase indicates that the
free energy of curvature and the hydrocarbon packing free
energy are of an intermediary value.
This work with FeLV fusion peptide supports the proposed
link between the mechanism of inverse cubic phase formation
and membrane fusion. It also indicates that bilayer thinning
may be important in the fusion pathway. This study only
deals with simpli¢ed peptide lipid interactions. In vivo, the
peptide is covalently bound to a larger fusion protein, which
is embedded in the viral membrane. During fusion, the primed
fusion peptide will interact, at least initially, with only the
outer membrane lea£et. In this experiment, the fusion peptide
is free to interact with both sides of multi-lamellar bilayers.
Nonetheless, these results may well represent many features of
the fundamental peptide membrane interactions but without
the same control and speci¢city.
Acknowledgements: We are grateful to Mrs. Sue Slawson for expert
technical assistance at SRS and Sasha Darkes for commenting on the
manuscript. The work was supported by grants from the Wellcome
Trust and the Central Laboratory of the Research Councils (CLRC).
References
[1] White, J.M. (1990) Annu. Rev. Physiol. 52, 675^697.
[2] Bullough, P.A., Hughson, F.M., Skehel, J.J. and Wiley, D.C.
(1994) Nature 371, 37^43.
[3] Chernomordik, L.V. and Zimmerberg, J. (1995) Curr. Opin.
Struct. Biol. 5, 541^547.
[4] Papadopoulos, D., Vail, W.J., Newton, C., Nir, S., Jacobson, K.,
Poste, G. and Lazo, R. (1977) Biochem. Biophys. Acta 465, 579^
598.
[5] Ellens, H., Bentz, J. and Szoka, F.C. (1986) Biochemistry 25,
4141^4147.
[6] Gagne¤, J., Stamatatos, L., Diacovo, T., Hui, S.W., Yeagle, P.L.
and Silvius, J.R. (1985) Biochemistry 24, 4400^4408.
[7] Hui, S.W., Stewart, T.P. and Boni, L.T. (1983) Chem. Phys.
Lipids 33, 113^126.
[8] Gruner, S.M., Tate, M.W., Kirk, G.L., So, P.T., Turner, D.C.
and Keane, D.T. (1988) Biochemistry 27, 2853^2866.
[9] Epand, R.F., Martin, I., Ruysschaert, J. and Epand, R.M. (1994)
Biochem. Biophys. Res. Commun. 205, 1938^1943.
[10] Epand, R.M. and Epand, R.F. (1994) Biochem. Biophys. Res.
Commun. 202, 1420^1425.
[11] Ellens, H., Siegel, D.P., Alford, D., Yeagle, P.L., Boni, L., Lis,
L.J., Quinn, P.J. and Bentz, J. (1989) Biochemistry 28, 3692^
3703.
[12] Epand, R.M. (1985) Biochemistry 24, 7092^7095.
[13] Siegel, D.P., Banschbach, J., Alford, D., Ellens, H., Lis, L.J.,
Quinn, P.J., Yeagle, P.L. and Bentz, J. (1989) Biochemistry 28,
3703^3709.
[14] Basa¤n‹ez, G., Nieva, J.L., Rivas, E., Alonso, A. and Gon‹i, F.M.
(1996) Biophys. J. 70, 2299^2306.
[15] Epand, R.M. (1986) Biosci. Rep. 6, 647^653.
[16] Verkleij, A.J. (1984) Biochem. Biophys. Acta 779, 43^63.
[17] Frederik, P.M., Stuart, M.C.A. and Verkleij, A.J. (1989) Bio-
chem. Biophys. Acta 979, 275^278.
[18] Frederik, P.M., Burger, K.N.J., Stuart, M.C.A. and Verkleij,
A.J. (1991) Biochem. Biophys. Acta 1062, 133^141.
[19] Siegel, D.P., Burns, J.L., Chestnut, M.H. and Talmon, Y. (1989)
Biophys. J. 56, 161^169.
[20] Siegel, D.P., Green, W.J. and Talman, Y. (1994) Biophys. J. 66,
402^414.
[21] Siegel, D.P. (1993) Biophys. J. 65, 2124^2140.
[22] Markin, V.S., Kozlov, M.M. and Borovjagin, V.L. (1984) Gen.
Physiol. Biophys. 5, 361^377.
[23] Siegel, D.P. and Epand, R.M. (1997) Biophys. J. 73, 3089^3111.
[24] Chernomordik, L.V., Vogel, S.S., Sokolov, N., Onaran, H.O.,
Leikina, E.A. and Zimmerberg, J. (1993) FEBS Lett. 318, 71^76.
[25] Chernomordik, L., Kozlov, M.M. and Zimmerberg, J. (1995)
J. Membr. Biol. 146, 1^14.
[26] Vogel, S.S., Leikina, E.A. and Chernomordik, L.V. (1993) J. Biol.
Chem. 268, 25764^25768.
[27] Davies, S.M.A., Epand, R.F., Bradshaw, J.P. and Epand, R.M.
(1998) Biochemistry 37, 5720^5729.
[28] Colotto, A., Martin, I., Ruysschaert, J., Sen, A., Hui, S.W. and
Epand, R.M. (1996) Biochemistry 35, 980^989.
[29] Gruner, S.M. (1985) Proc. Natl. Acad. Sci. USA 82, 3665^
3669.
[30] Shyamsunder, E., Gruner, S.M., Tate, M.W., Turner, D.C. and
So, P.T.C. (1988) Biochemistry 27, 2332^2336.
[31] Siegel, D.P. and Banschbach, J.L. (1990) Biochemistry 29, 5975^
5981.
[32] Fraser, R.D.B. and MacRae, T.P. (1981) Int. J. Biol. Macromol.
3, 193^200.
[33] Colotto, A. and Epand, R.M. (1997) Biochemistry 36, 7644^
7651.
[34] Davies, S.M.A., Kelly, S.M., Price, N.C. and Bradshaw, J.P.
(1998) FEBS Lett. 425, 418^425.
[35] Ellens, H., Siegel, D.P., Alford, D., Yeagle, P.L., Boni, L., Lis,
L.J., Quinn, P.J. and Bentz, J. (1989) Biochemistry 28, 3692^
3703.
[36] Hui, S.W., Stewart, T.P., Boni, L.T. and Yeagle, P.L. (1981)
Science 212, 921^923.
[37] Israelachvili, J.N. and McGuiggan, P.M. (1988) Science 241,
795^800.
[38] Leiken, S., Parsegian, V.A., Rau, D.C. and Rand, R.P. (1993)
Annu. Rev. Phys. Chem. 44, 369^395.
[39] Hughson, F.M. (1995) Curr. Biol. 5, 265^274.
[40] Bentz, J., Ellens, H. and Alford, D. (1990) FEBS Lett. 276, 1^5.
[41] Wu, Y., He, K., Ludtke, S.J. and Huang, H.W. (1995) Biophys.
J. 68, 2361^2369.
[42] Anderson, D.M., Gruner, S.M. and Leibler, S. (1988) Proc. Natl.
Acad. Sci. USA 85, 5364^5368.z
FEBS 22888 11-11-99
M.J.M. Darkes et al./FEBS Letters 461 (1999) 178^182182
